Clinical trials
Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 225 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT04881487Recruiting
Radiation treatment for local pancreatic cancer recurrence
This trial looks at additional treatment using a special type of focused radiation (stereotactic body radiation therapy) for pancreatic cancer that has come back only in the same area after surgery. It may help by controlling the local recurrence and possibly improving outcomes for people whose cancer has not spread elsewhere.
Amsterdam, North HollandAges 18 years+ - NCT04970056Recruiting
Pancreatic cancer risk and early-detection registry study
This study builds a database of people at higher risk for pancreatic cancer (or certain early warning findings) to help find better ways to detect the disease early. You may be asked to complete health questionnaires and possibly donate a blood/saliva/swab sample.
Phoenix, ArizonaAges 18–90 - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT06655233Recruiting
Exploring gut bacteria in pancreatic cancer tumors
This trial studies bacteria found inside pancreatic tumors to see if they can help diagnose or predict the course of the disease. You may be eligible if you have a suspected pancreatic cancer and need a special biopsy (EUS-FNB).
Hunan, HunanAges 18–80 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT05947825Enrolling by invitationPhase 2
Sitagliptin plus chemo for advanced pancreatic cancer
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
TianjingAges 18 years+ - NCT06472037RecruitingPhase 2
AG chemo plus immunotherapy and short radiation for locally advanced pancreatic cancer
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06467565RecruitingPhase 2
NALIRIFOX chemotherapy for locally advanced pancreatic cancer
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–70 - NCT06060405RecruitingPhase 2
Immunotherapy before surgery for pancreatic cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
Toronto, OntarioAges 18 years+ - NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT06393400RecruitingPhase 1
Stool transplant with chemotherapy for advanced pancreatic cancer
This study tests if giving patients a stool transplant (also called FMT) in capsules along with their first chemotherapy can help treat advanced pancreatic cancer that cannot be removed by surgery.
London, OntarioAges 18 years+ - NCT04990609RecruitingPhase 2
Study for pancreatic cancer using a biopsy-confirmed treatment approach
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
Houston, TexasAges 18 years+ - NCT07373691Enrolling by invitation
Scoring system study for advanced pancreatic cancer
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
ShanghaiAges 18 years+ - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT07587866Recruiting
Panuri Test for Suspected Pancreatic Cancer
This study tests a new diagnostic tool called Panuri to help detect pancreatic cancer in adults who have symptoms suggesting the disease. The test may help doctors identify pancreatic cancer earlier and more accurately.
BékéscsabaAges 18 years+ - NCT07155850Recruiting
Testing YntraDose before chemotherapy for advanced pancreas cancer
This trial tests a new treatment called YntraDose, given directly into the pancreas tumor before standard chemotherapy. It is for people with locally advanced pancreatic cancer that cannot be removed by surgery.
RomaAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Duarte, CaliforniaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 225 recruiting pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Ductal Adenocarcinoma
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.